Farmaci orfani e malattie rare: la situazione in Italia

Farmaci orfani e malattie rare: la situazione in Italia

Authors

  • S. Martina CESAV Centro di Economia Sanitaria Angelo e Angela Valenti, Istituto di Ricerche Farmacologiche Mario Negri, Ranica (BG)

  • C. Denti Centro di Ricerche Cliniche per le Malattie Rare “Aldo e Cele Daccò”, Istituto di Ricerche Farmacologiche Mario Negri, Ranica (BG)

  • E. Daina Centro di Ricerche Cliniche per le Malattie Rare “Aldo e Cele Daccò”, Istituto di Ricerche Farmacologiche Mario Negri, Ranica (BG)

  • L. Garattini CESAV Centro di Economia Sanitaria Angelo e Angela Valenti, Istituto di Ricerche Farmacologiche Mario Negri, Ranica (BG)



DOI:

https://doi.org/10.7175/fe.v2i4.738

Abstract

Aim of this study is to check the Italian market of the orphan drugs in connection with rare diseases. Data for the research have been found on the Food and Drug Administration Database, the Centro di Ricerche Cliniche per le Malattie Rare “Aldo e Cele Daccò” Database and L’informatore farmaceutico. This study also compared the Italian market with the American market, that counts the greater number of designated orphan drugs and commercial authorizations in the world. In Italy only 24 orphan drugs have been authorized by the Ministry of Health and the present work analyzes their definition under the economic profile, how many diseases and what kind of pathologies they can treat, the number of products on the market and if they are refundable or not.

Published

2001-12-15

How to Cite

Martina, S., Denti, C., Daina, E., & Garattini, L. (2001). Farmaci orfani e malattie rare: la situazione in Italia. Farmeconomia. Health Economics and Therapeutic Pathways, 2(4), 261–266. https://doi.org/10.7175/fe.v2i4.738

Issue

Vol. 2 No. 4 (2001)

Section

Review (Economic Analysis)

License

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
  4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)